NCT00693199已完成不适用
Effect of Amlodipine Monotherapy or Combined With Terazosin on Lower Urinary Tract Symptoms and Hypertension
Anhui Medical University1 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2006年7月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 360
- 试验地点
- 1
- 主要终点
- The primary efficacy outcomes were reductions in blood pressure and International Prostate Symptoms Score (IPSS) and sub-scores.
研究概览
简要总结
The aim of this study was to investigate the efficacy and safety of low dose amlodipine alone, or combined with low dose terazosin in male patients with both lower urinary tract symptoms and hypertension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Men 50 years or older
- •with LUTS [defined as International Prostate Symptom Score (IPSS) >= 10].
- •Stage 1 or 2 essential hypertension (SBP >= 140 mm Hg and < 180 mm Hg and/or DBP >= 90 mm Hg and < 110 mm Hg)
排除标准
- •A history of postural hypotension
- •Secondary hypertension
- •Prostate cancer
- •Prostate surgery or other intervention
- •Use of any agents to influence the LUTS symptoms in the last 4 weeks
- •Other severe diseases
研究组 & 干预措施
1
Experimental
干预措施: amlodipine (Drug)
2
Active Comparator
干预措施: terazosin (Drug)
3
Experimental
干预措施: amlodipine plus terazosin (Drug)
结局指标
主要结局
The primary efficacy outcomes were reductions in blood pressure and International Prostate Symptoms Score (IPSS) and sub-scores.
时间窗: 28th day after treatment
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential HypertensionHypertensionNCT00942344Hanmi Pharmaceutical Company Limited320
已完成
不适用
Effect of combination therapy with amlodipine and atorvastatin on blood pressure varaiability, vascular function and renal function in hypertensive patients with chronic kidney diseaseHypertension with chronic kidney disease (CKD stage 1-4)JPRN-UMIN000009045Yokohama city university hospital50
已完成
3 期
effects of amlodipine to reduce cardiac iron overloadMajor Thalasemia.Beta thalassemiaD56.1IRCT20190829044642N1Arak University of Medical Sciences30
已完成
不适用
Study of clinical utility of amlodipine OD 5mg tablet Chemiphar to the patients with essential hypertensioJPRN-UMIN000002626Shiba Palace Clinic50
已完成
1 期
CKD-330 Drug-Drug Interaction Study (Amlodipine)HypertensionNCT02064556Chong Kun Dang Pharmaceutical24